KKR to Present at the Morgan Stanley US Financials Conference 2025
NEW YORK, June 02, 2025--(BUSINESS WIRE)--KKR & Co. Inc. (NYSE: KKR) announced today that Adam Smith, Partner and Co-Head of Credit & Markets, will present at the Morgan Stanley US Financials Conference 2025 on Tuesday, June 10, 2025 at 9:00 AM ET.
A live webcast of the presentation will be available on the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. For those unable to listen to the live webcast, a replay will be available on the website shortly after the event.
Any questions regarding the webcast may be addressed to KKR's Investor Relations team at investor-relations@kkr.com.
ABOUT KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602760815/en/
Contacts
Investor Relations:Craig Larson+1 (877) 610-4910 (U.S.) / +1 (212) 230-9410investor-relations@kkr.com
Media:Julia Kosygina+ 1 (212) 750-8300media@kkr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Why ChargePoint (CHPT) Shares Are Sliding Today
Shares of EV charging solutions provider ChargePoint Holdings (NYSE:CHPT) fell 22% in the afternoon session after the company reported weak first quarter 2025 results: its revenue, EPS, and EBITDA missed. A 20% decline in Networked charging systems sales was responsible for most of the top line weakness observed in the quarter. Its revenue guidance for next quarter also fell short of Wall Street's estimates. Overall, this quarter could have been better. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy ChargePoint? Access our full analysis report here, it's free. ChargePoint's shares are extremely volatile and have had 75 moves greater than 5% over the last year. But moves this big are rare even for ChargePoint and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was 6 months ago when the stock gained 22.1% on the news that the company reported strong third-quarter results that exceeded analysts' revenue and EBITDA estimates. While sales declined year on year in the Networked charging systems business, the result came in well ahead of consensus estimates, indicating expectations were modest heading into earnings. However, the top line also benefited from strong double-digit growth in the subscription segment, which is more promising. On the other hand, its full-year operating income guidance was lowered, showing that the growth is less profitable than expected. The market seemed to be focused more on the top-line successes, and the stock was up as a result. ChargePoint is down 37.8% since the beginning of the year, and at $0.70 per share, it is trading 70.6% below its 52-week high of $2.37 from July 2024. Investors who bought $1,000 worth of ChargePoint's shares 5 years ago would now be looking at an investment worth $70.88. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Business Wire
36 minutes ago
- Business Wire
Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. ('Organon' or the 'Company') (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR ORGANON INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company's dividend payout, from $0.28 to $0.02 and would 'redirect those funds to debt reduction.' On this news, Organon's stock price fell $3.48, or 26.9%, to close at $9.45 per share on May 1, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Organon's optimistic reports of the dividend payout as the Company's 'number one priority,' were offset by Organon's newly implemented debt reduction strategy, thus, leading to a drastic decrease – over 70% – of the quarterly dividend; (2) Organon planned to prioritize debt reduction following the Company's acquisition of Dermavant; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Organon securities during the Class Period, you may move the Court no later than July 22, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
39 minutes ago
- Yahoo
Why Are Tilly's (TLYS) Shares Soaring Today
Shares of young adult apparel retailer Tilly's (NYSE:TLYS) jumped 10.9% in the afternoon session after the company reported impressive first quarter 2025 results and provided optimistic revenue and EPS guidance for the next quarter, which blew past analysts' expectations. Sales weakness improved as the company observed consistent traffic gains. The company was also betting on the seasonally strong Back-to-School Season to drive volume growth, further reinforcing the upbeat guidance despite ongoing store closures. On the other hand, the quarter's revenue, EPS, and EBITDA fell short of Wall Street's estimates. Zooming out, we think this was a mixed yet decent quarter. Is now the time to buy Tilly's? Access our full analysis report here, it's free. Tilly's shares are extremely volatile and have had 68 moves greater than 5% over the last year. But moves this big are rare even for Tilly's and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was 12 months ago when the stock dropped 10.6% on the news that the company reported first quarter earnings. EPS fell below analyst's expectations. While revenue came in narrowly ahead of Wall Street's estimates, top line growth continued to decline in absolute terms. Guidance was also weak as the earnings forecast for the next quarter missed analysts' expectations, disappointing investors. Management struck a not-so-confident tone, adding that it might be "difficult to improve our sales results in the near term." This is partly a result of the macroeconomic challenges experienced during the quarter. Overall, the results could have been better. Tilly's is down 67.2% since the beginning of the year, and at $1.49 per share, it is trading 76.2% below its 52-week high of $6.28 from July 2024. Investors who bought $1,000 worth of Tilly's shares 5 years ago would now be looking at an investment worth $233.52. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
